The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 27, 2017

Filed:

Apr. 30, 2014
Applicant:

Suhayl Dhib-jalbut, Princeton, NJ (US);

Inventor:

Suhayl Dhib-Jalbut, Princeton, NJ (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); A61K 38/16 (2006.01); G01N 33/564 (2006.01); A61K 38/07 (2006.01);
U.S. Cl.
CPC ...
A61K 38/16 (2013.01); A61K 38/07 (2013.01); G01N 33/564 (2013.01); G01N 2333/525 (2013.01); G01N 2333/54 (2013.01); G01N 2333/5428 (2013.01); G01N 2333/96466 (2013.01); G01N 2800/52 (2013.01); G01N 2800/60 (2013.01);
Abstract

A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer acetate hypo-/non-responder by measuring the value of a biomarker selected from the group consisting of IL-10 concentration, IL-17 concentration, IL-18 concentration, TNF-α concentration, BDNF concentration, caspase-1 concentration, IL-10/IL-18 ratio and IL-10/IL-17 ratio in the blood of the subject, and comparing the measured value to a reference value for the biomarker to identify the subject as a glatiramer acetate responder or a glatiramer acetate hypo-/non-responder, and continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is identified as a glatiramer acetate hypo-/non-responder.


Find Patent Forward Citations

Loading…